Trading Signals: NTLA Stock Price Prediction and Forecast (Fri. May. 6, 2016 - Fri. Oct. 27, 2023)(Intellia Therapeutics, Inc.)
| NTLA latest price $29.0000 (-0.48%) ($28.2300 - $29.6300) on Thu. May. 26, 2016. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 4.35% (three month average) | | RSI | 75 | | Latest Price | $29.0000(-0.48%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | NTLA advances 1.8% a day on average for past five trading days. | | Market Behavior | Normal for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support NTLA advance at 0% a week (0% probability)
ARKG(66%) IBB(59%) XBI(59%) ARKK(58%) IWO(57%) | | Factors Impacting NTLA price | NTLA will decline at least -2.175% in a week (0% probabilities).
VIXM(-13%) UUP(-8%) TLT(-8%) IPO(-3%) SHY(-2%) | | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -2.175% (StdDev 4.35%) | | Hourly BBV | 0 () | | Intraday Trend | -1.6% | | | | | |
|
| 5 Day Moving Average | $28.48(1.83%) | | 10 Day Moving Average | $27.23(6.5%) | | 20 Day Moving Average | $0(INF%) | | To recent high | -0.5% | | To recent low | 31.2% | | Market Cap | $1.935b | | | | | | |
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA. |